Table 1 Baseline characteristics
Overall (n = 675) | InSTI + TDF/FTC (n = 209) | RPV/FTC/TDF (n = 466) | p-value | |
|---|---|---|---|---|
Age (years) | 46.2 (39.9–51.6) | 48.7 (41.8–53.3) | 45.4 (39.2–50.7) | 0.0002 |
Male gender | 578(86%) | 174(83%) | 404(87%) | 0.238 |
HIV risk factor | <0.0001 | |||
MSM | 330(49%) | 78(37%) | 252(54%) | |
Heterosexual | 134(20%) | 38(18%) | 96(21%) | |
IDU | 88(13%) | 49(23%) | 39(8%) | |
Other/Unknown | 123(18%) | 44(21%) | 79(17%) | |
Years since HIV diagnosis | 10.3 (5.1–17.3) | 13.8 (6.6–22.5) | 9.1 (4.8–15.5) | <0.0001 |
History of AIDS defining events | 78(12%) | 26(12%) | 52(11%) | 0.696 |
Years of ART | 6.6 (3.3–14.1) | 10.1 (4.0–16.8) | 5.7 (3.0–11.9) | <0.0001 |
NRTI-experience | 661(98%) | 206(99%) | 455(98%) | 0.567 |
NNRTI-experience | 326 (48%) | 88 (42%) | 238 (51%) | 0.037 |
PI-experience | 533 (79%) | 193 (92%) | 340 (73%) | <0.0001 |
Years with HIV-RNA <50copies/mL | 3.07 (1.07–5.62) | 2.96 (0.77–6.12) | 3.09 (1.25–5.46) | 0.493 |
Time spent with residual viremia (%) | 47.8 (23.9–74.1) | 51.7 (22.1–74.2) | 46.4 (24.3–73.6) | 0.437 |
History of failure to NRTIs | 130 (19%) | 70 (34%) | 60 (13%) | <0.0001 |
History of failure to NNRTIs | 32 (5%) | 22 (11%) | 10 (2%) | <0.0001 |
History of failure to PIs | 110 (16%) | 54 (26%) | 56 (12%) | <0.0001 |
Type of treatment | <0.0001 | |||
PI-based | 438 (65%) | 172 (82%) | 266 (57%) | |
NNRTI-based | 205 (30%) | 24 (12%) | 181 (39%) | |
Other | 32 (5%) | 13 (6%) | 19 (4%) | |
Nadir CD4+ count (cell/μL) | 271 (160–384) | 228 (122–336) | 289 (205–397) | <0.0001 |
Zenith HIV-RNA before starting ART (log 10 copies/mL) | 4.85 (4.08–5.32) | 4.97 (4.11–5.40) | 4.80 (4.08–5.29) | 0.187 |
CD4+ (cell/μL) | 679 (517–868) | 663 (451–854) | 687 (542–870) | 0.017 |
HCV-Ab+ | 159 (24%) | 82 (39%) | 77 (17%) | <0.0001 |
ALP (U/L) | 87 (69–106) | 93 (73–110) | 86 (69–105) | 0.040 |
ALT (U/L) | 31 (22–47) | 34 (22–63) | 30 (22–43) | 0.001 |
Total bilirubin (mg/dL) | 0.57 (0.34–1.44) | 0.68 (0.41–1.71) | 0.50 (0.32–1.37) | 0.003 |
FIB-4 | 0.89 (0.65–1.27) | 1.08 (0.72–1.64) | 0.84 (0.61–1.12) | <0.0001 |
eGFR (ml/min/1.73m 2 ) | 104 (93–113) | 102 (90–111) | 105 (95–114) | 0.013 |
Proteinuria (mg/dL) | 5 (0–10) | 5 (0–10) | 5 (0–10) | 0.858 |
Total cholesterol (mg/dL) | 191 (162–219) | 191 (159–216) | 191 (164–222) | 0.168 |
LDL cholesterol (mg/dL) | 119 (95–144) | 117 (91–145) | 120 (97–144) | 0.407 |
HDL cholesterol (mg/dL) | 45 (38–55) | 42 (36–51) | 47 (40–58) | <0.0001 |
Total/HDL cholesterol | 4.25 (3.37–5.18) | 4.56 (3.43–5.23) | 4.18 (3.36–5.07) | 0.045 |
Triglycerides (mg/dL) | 122 (86–180) | 137 (98–215) | 117 (82–166) | 0.0002 |
Glucose (mg/dL) | 85 (78–93) | 87 (80–96) | 84 (78–91) | 0.001 |
Hemoglobin (10 9 /L) | 15.1 (14.1–15.7) | 14.9 (14.1–15.7) | 15.1 (14.2–15.7) | 0.315 |
Phosphate (mmol/L) | 0.98 (0.86–1.10) | 0.99 (0.85–1.13) | 0.98 (0.87–10.8) | 0.621 |